Aviceda Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $207.5M
Overview
Develops glycan-based nanotherapeutics to modulate ocular immunity for retinal diseases like geographic atrophy.
OphthalmologyImmunology
Technology Platform
A nanoparticle platform coated with specific glycans designed to selectively bind and modulate hyperactive immune cells in the retina to treat degenerative diseases.
Funding History
1Total raised:$207.5M
Venture$207.5M
Opportunities
Large and growing market for geographic atrophy treatment with significant need for safer, more effective therapies.
Risk Factors
Clinical failure in a competitive late-stage trial or inability to differentiate from established complement inhibitors.
Competitive Landscape
Competes directly with approved and pipeline complement inhibitors for geographic atrophy, requiring demonstration of clinical superiority or better safety.